Exelixis, Inc. (EXEL)
44.16
+0.38
(+0.87%)
USD |
NASDAQ |
Jan 21, 10:54
Exelixis EPS Diluted (Quarterly): 0.695 for Sept. 30, 2025
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Vanda Pharmaceuticals, Inc. | -0.3822 |
| ADMA Biologics, Inc. | 0.1489 |
| Aldeyra Therapeutics, Inc. | -0.1279 |
| Natera, Inc. | -0.6381 |
| Merck & Co., Inc. | 2.316 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 193.58M |
| Revenue (Quarterly) | 597.76M |
| Total Expenses (Quarterly) | 404.18M |
| Enterprise Value | 10.93B |
| Gross Profit Margin (Quarterly) | 96.89% |
| Profit Margin (Quarterly) | 32.38% |
| Earnings Yield | 5.38% |
| Operating Earnings Yield | 6.49% |
| Normalized Earnings Yield | 5.493 |